SAN FRANCISCO — A Swiss pharmaceutical company has brought in high caliber reinforcements as it takes its battle over a $407 million business tort judgment to the California Supreme Court.
Quinn Emanuel Urquhart & Sullivan partner Kathleen Sullivan has joined Actelion’s team at Mayer Brown in a last-ditch attack on a jury award that they say “discourages businesses from investing in California, especially in the pharmaceutical and high-tech sectors that are so vital to the state’s economy.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
